Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Roberto Collado Borrell"'
Autor:
Javier De Castro, Amelia Insa, Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Alex Martínez, Elena Fernandez, Ivana Sullivan, Natalia Arrabal, David Carcedo, Alba Manzaneque
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background There are scarce data of the costs of non-small cell lung cancer (NSCLC) recurrence in Spain. The objective of this study is to assess the economic burden of disease recurrence, for both locoregional and/or metastatic relapses, af
Externí odkaz:
https://doaj.org/article/6b5d735a63a64f3c8aa7226d4eca7c2b
Autor:
Elena Ramos-Ruperez, Vicente Escudero-Vilaplana, Paula Ruiz-Briones, Roberto Collado-Borrell, Cristina Villanueva-Bueno, José Luis Revuelta-Herrero, Eva González-Haba, Xandra Garcia-Gonzalez, Sara Ibañez-Garcia, Sara Perez-Ramirez, Eduardo Zatarain-Nicolás, Ana Herranz, María Sanjurjo
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectiveThe management of cardiotoxicity concerning the use of oral antineoplastic agents (OAAs) is a challenge for healthcare professionals. Our objective was to create a comprehensive medication management guide with dose adjustment recommendation
Externí odkaz:
https://doaj.org/article/53a5cf4d22e14290a294cade5ade3733
Autor:
Cristina Villanueva-Bueno, Roberto Collado-Borrell, Vicente Escudero-Vilaplana, José Luis Revuelta-Herrero, María Belén Marzal-Alfaro, Eva González-Haba, José Ángel Arranz-Arija, Santiago Osorio, Ana Herranz-Alonso, María Sanjurjo-Saez
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
ObjectiveThis study aims to analyze the impact of the eOncosalud app on the management and follow-up of adverse effects (AE) in patients receiving oral antineoplastic agents.Material and methodsWe performed an observational, prospective study of canc
Externí odkaz:
https://doaj.org/article/f07822eba5894259b777035de08df288
Autor:
Vicente Escudero-Vilaplana, Lorena Romero-Medrano, Cristina Villanueva-Bueno, Marta Rodríguez de Diago, Alberto Yánez-Montesdeoca, Roberto Collado-Borrell, Juan José Campaña-Montes, Belén Marzal-Alfaro, José Luis Revuelta-Herrero, Antonio Calles, Mar Galera, Rosa Álvarez, Ana Herranz, María Sanjurjo, Antonio Artés-Rodríguez
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundWe have defined a project to develop a mobile app that continually records smartphone parameters which may help define the Eastern Cooperative Oncology Group performance status (ECOG-PS) and the health-related quality of life (HRQoL), witho
Externí odkaz:
https://doaj.org/article/7a253ab6b9a4432797ea9e4d55156567
Autor:
Sebastián García-Sánchez, Roberto Collado-Borrell, Eva González-Haba, José Luis Revuelta-Herrero, Vicente Escudero-Vilaplana, María Belén Marzal-Alfaro, María Norberta Sánchez-Fresneda, Ana Mur-Mur, Ana Herranz, Miguel Martín, María Sanjurjo
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundOncology clinical trials can lead to relevant financial savings in drug acquisition for healthcare providers. Considerable methodological heterogeneity is observed among previous studies estimating these savings.MethodsWe developed a method
Externí odkaz:
https://doaj.org/article/ef21ba18017e49daaff1a9ba9314cef3
Autor:
Vicente Escudero-Vilaplana, Elsa Bernal, Gema Casado, Roberto Collado-Borrell, Raúl Diez-Fernández, Ana Beatriz Fernández Román, Carlos Folguera, Lucía González-Cortijo, Marta Herrero-Fernández, Gloria Marquina, Concepción Martínez Nieto, Miguel Angel Rodríguez, Ana Rosa Rubio, Patricia Sanmartin-Fenollera, Maria José Vazquez Castillo, Marta Comellas, Eva Maria Guerra
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposeAdvanced ovarian cancer (AOC) and its treatment cause several symptoms and impact on patients’ health-related quality of life (HRQoL). We aim to reach a consensus on the most relevant patient-reported outcome (PROs), the corresponding measur
Externí odkaz:
https://doaj.org/article/7a86e149e60149078f3bbd3e99c0b93a
Autor:
Álvaro Narrillos-Moraza, Patricia Gómez-Martínez-Sagrera, Miguel Ángel Amor-García, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Cristina Villanueva-Bueno, Ignacio Gómez-Centurión, Ana Herranz-Alonso, María Sanjurjo-Sáez
Publikováno v:
JMIR mHealth and uHealth, Vol 10, Iss 2, p e32826 (2022)
BackgroundHematological conditions are prevalent disorders that are associated with significant comorbidities and have a major impact on patient care. Concerning new tools for the care of these patients, the number of health apps aimed at hematologic
Externí odkaz:
https://doaj.org/article/2da972dc72764be99224d7fddafc2e13
Autor:
María Belen Marzal-Alfaro, Vicente Escudero-Vilaplana, Jose Luis Revuelta-Herrero, Roberto Collado-Borrell, Ana Herranz-Alonso, Maria Sanjurjo-Saez
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
PurposeThe use process for chimeric antigen receptor T (CAR-T) cell drugs is complex and has been associated with a number of potentially severe complications, which requires management by a multidisciplinary team. Pharmacists are a key element in th
Externí odkaz:
https://doaj.org/article/e5a63c2b25e74892b585ad18dcfff5dd
Autor:
Vicente Escudero-Vilaplana, Antonio Calles, Roberto Collado-Borrell, María Belén Marzal-Alfaro, Carlos Polanco, Carmen Garrido, Jorge Suarez, Aurora Ortiz, Marilena Appierto, Marta Comellas, Luis Lizán
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Purpose: Lung cancer (LC) and its treatment impose a significant burden on patients' life. However, patient-centered outcomes are rarely collected during patient follow-up. Filling this gap, the International Consortium for Health Outcomes Measuremen
Externí odkaz:
https://doaj.org/article/dd1f2e5a1aa94c6a994357f955246977
Autor:
Beatriz López Centeno, Roberto Collado Borrell, Montserrat Pérez Encinas, Maria Luisa Gutiérrez García, Patricia Sanmartin Fenollera
Publikováno v:
Farmacia Hospitalaria, Vol 40, Iss 4, Pp 279-286 (2016)
Objective: To compare the effectiveness and renal safety of treatment with tenofovir versus entecavir in patients with chronic hepatitis-B. Methods: Retrospective study in hepatitis-B patients who initiated treatment with tenofovir or entecavir since
Externí odkaz:
https://doaj.org/article/aa8a7ec4cae44dcfac0aaa0bd0f8ca1f